No Data
No Data
BioMarin Pharmaceutical (NASDAQ:BMRN) Seems To Use Debt Rather Sparingly
Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (CATX) and BioMarin Pharmaceutical (BMRN)
Citi Maintains Biomarin Pharmaceutical(BMRN.US) With Hold Rating, Maintains Target Price $82
Insider Sale: GVP of $BMRN Sells 1,295 Shares
BioMarin Pharmaceutical (BMRN): Among Paul Singer's Latest Portfolio's Top Stock Picks
BioMarin Presents New Data Demonstrating Favorable Safety And Strong Adherence In Real-World Clinical Practice With VOXZOGO In Children Under 3 With Achondroplasia At 2025 ACMG Annual Clinical Genetics Meeting